

Formycon. The Biosimilar Experts.

Financial Statements of Formycon AG
for the period from January 1, 2024
to December 31, 2024



Table of contents

Financial Statements of Formycon AG for the period from January 1, 2024 to December 31, 2024

Balance Sheet — *Assets* in € K

	Dec. 31, 2024	Dec. 31, 2023
A. Fixed assets		
I. Intangible assets		
Purchased concessions, industrial property rights, and similar rights and assets, as well as licenses for such rights and assets	466	871
	466	**871**
II. Property, plant and equipment		
Land and buildings, including property-like rights and buildings on third-party land	412	73
Technical equipment and machinery	3,012	2,988
Other plant, production equipment and office equipment	1,383	987
Advance payments	0	113
	4,808	**4,161**
III. Financial assets		
Shares in affiliated companies	348,439	463,533
Loans to affiliated companies	68,419	93,300
Investment participations	151,920	163,133
	568,778	**719,966**
B. Current assets		
I. Inventories		
Raw materials, consumables and supplies	388	467
Unfinished products and services	0	665
Advance payments	20,967	9,690
	21,355	**10,822**
II. Receivables and other assets		
Trade accounts receivable	3,576	22
Receivables from affiliated companies	16,046	17,357
Other assets	3,693	4,190
	23,315	**21,569**
III. Cash and cash equivalents	**30,623**	**21,494**
C. Prepaid expenses and deferred items	**1,098**	**546**
	650,442	**779,428**

Balance Sheet — *Shareholders equity and liabilities* in € K

	Dec. 31, 2024	Dec. 31, 2023
A. Equity		
I. Subscribed capital[1]	17,664	16,053
II. Capital reserve	560,813	479,338
III. Accumulated loss carryforward	-260,496	-131,476
	317,982	**363,915**
B. Provisions		
I. Other provisions	313,595	376,587
of which due in more than one year: € 311.369K (Vorjahr: € 341,839K)		
	313,595	**376,587**
C. Liabilities		
I. Trade accounts payable	5,270	7,827
of which due within one year: € 5,270K (prior year: € 7,827K)		
II. Liabilities toward affiliated companies	12,000	9,000
III. Other liabilities	1,595	22,099
of which due within one year: € 940K (prior year: € 21,383K)		
of which due in more than one year: € 655K (prior year: € 716K)		
of which from taxes: € 212K (prior year: € 0K)		
of which relating to social security: € 1K (prior year: € 63K)		
	18,865	**38,926**
	650,442	**779,428**

[1] Conditional Capital 2019: € 4,000,000.00
Conditional Capital 2015: € 225,450.00

Income Statement for the period from January 1, 2024 to December 31, 2024

	Fiscal year 2024 in € K	Prior year in € K
Sales revenue	33,906	37,917
Increase or decrease in inventories of finished and unfinished products	0	-473
Other operating income *'- of which income attributable to foreign currency translation: € 63K (prior year: € 70K)*	842	3,461
Cost of materials		
a) Cost of raw materials, consumables and supplies and of purchased goods	3,287	3,863
b) Cost of purchased services	48,571	31,882
	51,858	**35,745**
Staff expenses		
a) Wages and salaries	20,834	18,053
b) Social contributions and costs for retirement benefits *- of which for retirement benefits: € 584K (prior year: € 205K)*	4,125	3,489
	24,959	**21,542**
Depreciation, amortization and writedowns of intangible assets and on property plant and equipment	1,380	974
Other operating expenses *'- of which expense arising from foreign currency translation: € 104K (prior year: € 55K)*	17,684	14,596
Income from investment participations *'- of which from affiliated companies € 0K (prior year: € 0K)*	7,125	3,580
Other interest and similar income *'- of which from affiliated companies € 492K (prior year: € 206K)*	52,575	40,015
Writedowns of financial assets and of securities held in current assets	126,307	177,015
Interest and similar expense	1,273	1,720
Taxes on income	1	-3
Loss after tax	**-129,014**	**-166,143**
Other taxes	5	5
Annual net loss	**-129,019**	**-166,148**
Loss carryforward from prior year	-131,476	-34,671
Accumulated loss carryforward	**-260,496**	**-131,476**

Notes to the Financial Statements of Formycon AG for the period from January 1, 2024 to December 31, 2024

1. General information about the Company

Formycon AG ("Formycon" or the "Company"), together with the subsidiary companies within its scope of consolidation (the "Group"), is a leading independent developer of high-quality biosimilar drugs, meaning follow-on products to biopharmaceuticals already on the market.

Formycon AG has its registered offices in Martinsried/Planegg, Germany, and is entered into the commercial register (Handelsregister) of the District Court of Munich under number HRB 200801. The Company's shares are listed on the Frankfurt Stock Exchange in the Prime Standard segment (German securities identifier (WKN): A1EWVY, ticker symbol: FYB, ISIN: DE000A1EWVY8).

To the Company's knowledge, specifically based upon voting rights notifications pursuant to sec. 20 of the German Stock Corporation Act (Aktiengesetz) received up until the date of these Financial statements, none of the Company's shareholders holds more than one quarter of the Company's total shares.

Furthermore, the Company has not received any subsequent voting rights notifications pursuant to sec. 33 of the German Securities Trading Act (Wertpapierhandelsgesetz) since its admission to the Prime Standard segment of the Frankfurt Stock Exchange, and thus there have not been, to the Company's knowledge, any changes compared to the prospectus for admission to trading.

2. General information about the content and structure of these Financial Statements

These Financial Statements, presented here in translation from the German original , have been prepared in accordance with sections 242 et seq. of the German Commercial Code (Handelsgesetzbuch, HGB) under observance of the supplementary provisions of sections 264 et seq. of the Commercial Code applicable to large corporations as well as sections 150 et seq. of the Stock Corporation Act (AktG). The Income Statement has been prepared using the total expenditure format in accordance with sec. 275 para. 2 of the Commercial Code. The Company's financial statements are prepared in euros (€) and presented here in thousands of euros (€ K).

3. Balance sheet presentation and valuation methods

Foreign currency translation

Assets and liabilities denominated in foreign currency are translated into euros at the average spot exchange rate on the day of their original posting. Changes in exchange rates between then and the balance sheet date are reflected by write-downs of assets or write-ups of liabilities only for amounts due in more than one year and only to the extent necessary so that valuation on the balance sheet date is without losses. Items due within a period of less than one year are translated at the average spot exchange rate as of the date of the financial statements. The resulting income or expense arising from currency translation is shown separately in the Income Statement under other operating income or expenses.

Derivatives

The Company did not hold any derivative financial instruments as of December 31, 2024.

Principles of balance sheet presentation and valuation

The accounting and valuation methods applied to the prior fiscal year were continued in the reported fiscal year. The Balance Sheet includes all assets, all liabilities and all prepaid and deferred items. Assets and liabilities are valued individually. The valuation of assets and liabilities takes all risks into account which are identifiable based on the principles of prudent business judgment.

Fixed assets

Purchased intangible assets (including software and licenses) are capitalized at their cost of acquisition and amortized based upon expected useful lifespans of three to five years.

No use has been made of the elective right under sec. 248 para. 2 of the Commercial Code to capitalize self-produced intangible assets.

Property, plant and equipment are valued at their cost of acquisition, less accumulated depreciation. The depreciation of all moveable assets is linear, with depreciation in the year of acquisition on a pro rata basis. In the event of any impairment in value which is expected to be permanent, the respective asset is written down to the lower fair value.

Scheduled depreciation for significant asset types is based on the following useful economic lifes:

Useful economic lifes	
Larger laboratory equipment, cooling equipment and laboratory furnishings	10 years
Smaller laboratory equipment	5 years
Computer servers	7 years
Small electronics (laptops, PCs, etc.)	3 years
Furniture and furnishings	10 years
Low-value items with cost of acquisition below € 800	Immediate write-off

Financial assets are stated at their cost of acquisition, or should there be an impairment in value, regardless of whether it is expected to be permanent or temporary, written down to the lower fair value. Should the reason for an impairment no longer apply, the impairment write-down is reversed.

Current assets

Raw materials, consumables and supplies as well as purchased goods in inventories are valued at their average cost of acquisition, insofar as a write-down to a lower value as of the balance sheet closing date is not required. Finished and unfinished products are valued at their cost of production in accordance with sec. 255 para. 2 sentence 2 of the Commercial Code.

Receivables and other assets are valued at the lower of nominal or fair value. In the case of doubtful receivables, bad debt allowances are made individually.

Cash and cash equivalents are stated at their nominal value.

Prepaid expenses

Expenditures incurred before the period closing date are recorded as prepaid expenses if the expense is specifically for a subsequent time period.

Deferred taxes

The calculation of deferred taxes as of December 31, 2024, in accordance with sec. 274 of the Commercial Code, is based upon timing differences between balance sheet items as these are stipulated under the Commercial Code and under German tax law. The resulting cumulative deferred tax benefit (deferred tax asset) and cumulative deferred tax burden (deferred tax liability) are determined on a net basis in accordance with sec. 274 para. 1 sentence 3 of the Commercial Code. The resulting differences are substantially the result of tax-loss carryforwards available to offset future profits and thus to reduce future trade tax and corporate tax obligations. Deferred tax assets were determined using assumed tax rates of 10.85% and 15.83% respectively. As in the prior fiscal year, the Company exercised its elective right under sec. 274 of the Commercial Code regarding the recognition of deferred tax assets and thus no deferred tax assets were recognized for the fiscal year.

Provisions

The provisions take into account all uncertain obligations and all identifiable risks. These are stated at the amount required for their fulfillment using prudent business judgment, including future increases in prices and costs. Provisions due after more than one year are discounted from the time of their expected fulfillment at the average market interest rate over the past seven fiscal years.

Liabilities

Liabilities are stated at the amount required for their fulfillment.

4. Additional notes to the Balance Sheet

Fixed assets

A Schedule of Fixed Assets, including depreciation and amortization taken in the current fiscal year, is provided as Attachment 1 to these Notes.

Financial assets consist substantially of shareholdings and investment participations in associated companies and are regularly reviewed for potential impairments. As part of the review as of December 31, 2024, required impairments were identified for the Company's investment participation in Bioeq AG as well as for its shareholding in subsidiary company FYB202 Project GmbH.

Receivables and other assets

The remaining term of receivables and other assets, and their relationship to other balance sheet items, is shown in the Schedule of Receivables included as Attachment 2.

Shareholders Equity

Information required per sec. 160 of the Stock Corporation Act

Number of shares outstanding
The Company has registered capital (Grundkapital) of € 17,664,427.00, which is divided into 17,664,427 bearer shares without par value.

By official entry into the Company's commercial register on February 8, 2024, the Company's registered capital was increased by € 1,603,877.00 through a partial utilization of the Approved Capital 2023. The shares were issued through a private placement. The capital increase took place at an issuance price of € 51.65 per share.

Approved Capital 2024
By resolution of the Annual General Meeting of June 12, 2024, the Executive Board is authorized, subject to the approval of the Supervisory Board, to increase the Company's registered capital one or more times at any time until June 11, 2029, and by no more than a total of € 8,828,451.00, through the issuance of up to 8,828,451 new no-par-value common bearer shares, against contributions in cash and/or in kind (the "Approved Capital 2024"). The Company's shareholders shall, in general, be granted subscription rights (which may also be by way of indirect subscription rights pursuant to sec. 186 para. 5 sentence 1 of the Stock Corporation Act). Notwithstanding the foregoing, the Executive Board shall be authorized, subject to the approval of the Supervisory Board, to fully or partly exclude the general statutory subscription rights of shareholders in the following specific cases:

— For the exclusion of fractional shares from subscription rights.

— In the case of capital increases against non-cash contributions for the issuance and granting of shares as consideration for the purchase of companies, parts of companies, equity interests in companies, or other assets or rights.

— In the case of capital increases made against cash contributions, provided that the issuance price of the new shares is not significantly lower than the stock exchange price at the time that the issuance price is determined and that the new shares issued under exclusion of subscription rights pursuant to sec. 186 para. 3 sentence 4 of the Stock Corporation Act do not exceed 10% of the Company's share capital, either at the time of entry into effect or at the time of exercise. The calculation of this 10% limit shall include (a) any shares which are issued or sold during the term of this authorization under an exclusion of subscription rights through the direct application of, and in accordance with, sec. 186 para. 3 sentence 4 of the Stock Corporation Act, and/or (b) any shares issued, or which may be issued, to fulfill the Company's obligations arising from the exercise of warrants and/or conversion rights, or other stock option rights or obligations, arising from bonds or profit participation rights, provided that these financial instruments have been issued subsequent to the entry into force of this authorization and under exclusion of subscription rights pursuant to sec. 186 para. 3 sentence 4 of the Stock Corporation Act.

— In the case of capital increases made against cash contributions, insofar as necessary to grant sufficient shares to holders of bonds or profit participation rights with warrants and/or conversion rights, or involving other stock option rights or obligations, and issued by the Company or by a direct or indirect subsidiary thereof, to the extent that they would be entitled as shareholders upon exercise of the relevant option or conversion right or fulfillment of option or conversion obligation, or following any right to substitute which the Company may have.

— For the granting of shares issued in lieu of cash dividends (scrip dividends), whereby shareholders are offered the option of contributing their dividend entitlement (in whole or in part) to the Company as a contribution in kind against the granting of new shares from approved capital.

The Executive Board is authorized, subject to the approval of the Supervisory Board, to determine further details regarding the specific implementation of any such capital increase and issuance of new shares, including the issuance price, as well as regarding the rights of shareholders thereunder. The Supervisory Board is further authorized to amend the Company's Articles of Incorporation to reflect any such increase in registered capital and corresponding decrease in Approved Capital 2023 in the event of any such full or partial utilization of the Approved Capital 2023 or in the event of its expiry.

Number of subscription rights per sec. § 192 para. 2 no. 1 of the Stock Corporation Act

Conditional Capital 2022
By resolution of the Annual General Meeting of June 30, 2022, the Company's registered capital was conditionally increased by a maximum of € 6,497,125.00 (the "Conditional Capital 2022").

This conditional capital increase shall serve for the granting of shares to holders of convertible bonds and/or bonds with attached warrants issued by the Company, or by a group company within the meaning of sec. 18 of the Stock Corporation Act, on the basis of the corresponding authorization resolved by the Annual General Meeting on June 30, 2022 and at any time until June 29, 2027, which become due upon the exercise of bondholder conversion and/or option rights, or upon fulfillment of conversion or subscription obligations, or upon the exercise by the Company of its optional rights to redeem bonds, in whole or in part, through the granting of Company shares in lieu of cash. The conversion or option exercise price at which the new shares are issued shall be determined in accordance with the authorizing shareholder resolution. Capital increases under the Conditional Capital 2022 shall be carried out only to the extent necessary for the exercise of conversion or option rights, or for the fulfillment by creditors or bondholders of conversion or subscription obligations, or for the exercise by the Company of its optional rights to redeem bonds, in whole or in part, through the granting of new Company shares to holders of convertible bonds and/or bonds with attached warrants as consideration due and only insofar as such consideration due is not granted in the form of cash or existing treasury shares, or as shares of another listed company as substitute consideration. Although newly issued shares should, in principle, participate in profits from the beginning of the fiscal year during which they are issued, any shares newly issued on the basis of a bond conversion or warrant exercise declared prior to the annual general meeting of the Company in which a resolution is passed regarding the application of retained profits from the prior financial year shall also be entitled to participate in any dividends declared for the prior fiscal year. To the extent legally permissible, the Board of Management may, with the approval of the Supervisory Board, determine the profit participation of such newly issued shares in deviation from sec. 60 para. 2 of the Stock Corporation Act. The Executive Board is authorized, subject to the approval of the Supervisory Board, to determine further details regarding the specific implementation of any capital increases hereunder.

Number of subscription rights per sec. § 192 para. 2 no. 3 of the Stock Corporation Act

Conditional Capital 2015
By resolution of the Annual General Meeting of June 30, 2015, the Company's registered capital was conditionally increased by a maximum of € 376,000 for the issuance of a maximum of 376,000 new no-par-value bearer shares (the "Conditional Capital 2015"). The Conditional Capital 2015 serves exclusively to secure subscription rights (stock options) granted to members of the Executive Board and Company employees, as well as executives and employees of Company subsidiaries and affiliates, under the authority granted by resolution of the Annual General Meeting of June 30, 2015 to issue such stock options at any time up to and including June 29, 2020 (the "Stock Option Plan 2015"). This capital increase is conditional upon such subscription rights having been issued and upon the exercise of such subscription rights by the holders thereof, and further provided that the Company does not grant treasury shares or provide a cash settlement in fulfillment of such subscription rights. The newly issued shares shall participate in profits from the start of the fiscal year for which, at the time of their issuance, no resolution has yet been taken by the Annual General Meeting as to the application of retained profits. The Executive Board is authorized, subject to approval of the Supervisory Board, to determine further details regarding the specific implementation of any such contingent capital increase. In the case of such subscription rights (stock options) being granted to

Executive Board members, the Supervisory Board is similarly authorized. The Supervisory Board is further authorized to amend the Company's articles of incorporation to reflect such utilization of conditional capital. During the fiscal year, a total of 7,525 shares were subscribed under the Conditional Capital 2015.

Thus, as of the period closing date, a total of 195,450 stock options remained issued under the Conditional Capital 2015 and neither expired nor exercised.

Conditional Capital 2020
The Company's registered capital was conditionally increased by a maximum of € 724,000 for the issuance of a maximum of 724,000 new no-par-value bearer shares (the "Conditional Capital 2020"). The Conditional Capital 2020 serves exclusively to secure subscription rights (stock options) granted to members of the Executive Board and Company employees, as well as executives and employees of Company subsidiaries and affiliates, under the authority granted by resolution of the Annual General Meeting of December 10, 2020 to issue such stock options at any time up to and including December 9, 2025 (the "Stock Option Plan 2020"). This capital increase is conditional upon such subscription rights having been issued and upon the exercise of such subscription rights by the holders thereof, and further provided that the Company does not grant treasury shares or provide a cash settlement in fulfillment of such subscription rights. The newly issued shares shall participate in profits from the start of the fiscal year for which, at the time of their issuance, no resolution has yet been taken by the Annual General Meeting as to the application of retained profits. The Executive Board is authorized, subject to approval of the Supervisory Board, to determine further details regarding the specific implementation of any such contingent capital increase. In the case of such subscription rights (stock options) being granted to Executive Board members, the Supervisory Board is similarly authorized. The Supervisory Board is further authorized to amend the Company's articles of incorporation to reflect such utilization of conditional capital.

During the fiscal year, 2,000 previously issued stock options expired, and thus as of the period closing date, a total of 230,000 stock options remained issued under the Conditional Capital 2020 and neither expired nor exercised.

Provisions

Other provisions are substantially comprised of the following:

Other provisions in € K

	Dec. 31, 2024	Dec. 31, 2023
Bonuses	1,999	1,429
Accrued vacation	499	423
Safekeeping obligations	202	198
Outstanding invoices	8,882	3,369
Audit and advisory costs	691	406
Occupational cooperative and other social expenses	117	72
Miscellaneous staff provisions	59	249
Earn-out FYB202	76,274	107,936
Earn-Out Bioeq AG	229,084	262,505
Total	**313,595**	**376,587**

The provisions for the future contingent purchase price payments ("earn-out") for the acquired shareholdings in Bioeq AG and FYB202 Project GmbH are regularly revalued based on expected cash flows. The changes in value arising from this revaluation are included in income as "other interest and similar income" or "interest and similar" expense. Aside from this revaluation, contingent purchase price payments for the shares in Bioeq AG amounting to € 20,807K were made during the financial year.

Liabilities

The remaining term of liabilities, along with their collateralization through liens or similar rights and their relationship to other balance sheet items, is shown in the Schedule of Liabilities included as Attachment 3 to these Notes.

Contingent liabilities

The Company has issued a letter of comfort (Patronatserklärung) in support of its subsidiaries Formycon Project 201 GmbH and Formycon Project 203 GmbH. To the best of our knowledge, the respective companies will be able, in all cases, to fulfill their underlying obligations. Claims thereunder are thus not anticipated.

Other financial obligations

The total amount of other financial obligations, within the meaning of sec. 285 sentence 1 no. 3a of the Commercial Code, results from contractual obligations for ongoing performance. For obligations up to one year, the total amount is € 1,384K, for obligations between one and five years € 4,271K, and for obligations beyond five years, € 0K.

5. Additional notes to the Income Statement

Sales revenue
The Company generates sales revenue exclusively from the provision of services in the field of biosimilar development. All parent-level revenue is generated within Germany.

Other operating income
Other operating income results primarily from the reversal of provisions from previous years and the recognition of pricvate usage of company vehicles as non-cash benefit. The reversal of provisions relates to a provision of € 386K for services whose fulfillment was successfully contested by the company due to poor performance by the service provider.

Cost of materials
Cost of materials includes expenses for raw materials and supplies, primarily for original product reference material used in the development process and for laboratory consumables, as well as for services purchased from external providers in support of the Company's development efforts.

Other operating expenses
Other operating expenses consist primarily of general and administrative costs, building costs, and legal and consulting fees.

Research and development
Total research and development costs during the reporting period were € 78,197K.

Other interest and similar income
Other interest and similar income largely consists of the gain recognized from a reduction in the amount of € 48,487K (2023: € 36,993K) in the provision for contingent purchase price payment obligations.

Writedowns of financial assets and of securities held in current assets
During the fiscal year, impairment losses were recorded in the amount of € 126,307K (2023: € 177,015K) on the Company's investment participation in Bioeq AG and shareholding in FYB202 Project GmbH.

6. Other information

Number of staff

Sec. 285 no. 7 of the Commercial Code requires the following information regarding the average number of staff during the reporting period:

Average number of staff

	Fiscal year 2024	Fiscal year 2023
Administration	47	39
Research and development	188	184
Total company staff	**235**	**223**

Information on the Executive Board and Supervisory Board

Information on members of the Executive Board per sec. 285 no. 10 of the Commercial Code:

— **Dr. Stefan Glombitza,** residing in Holzkirchen, Chief Executive Officer (since July 1, 2022**)**

— **Nicola Mikulcik**, residing in Munich, Chief Business Officer (since June 1, 2022)

— **Dr. Andreas Seidl**, residing in Oberhaching, Chief Scientific Officer (since July 1, 2022)

— **Ralph Enno Spillner**, residing in Neuried, Chief Financial Officer (since April 1, 2023)

Information on members of the Supervisory Board per sec. 285 no. 10 of the Commercial Code:

— **Dr. Olaf Stiller**, residing in Marburg
(Chair until June 12, 2024)
Member of the executive board of Paedi Protect AG

— **Peter Wendeln**, residing in Oldenburg
(Deputy Chair until June 12, 2024)
Managing partner, Wendeln & Cie. Asset Management GmbH

— **Klaus Röhrig**, residing in Vienna (Austria)
(member since December 10, 2020)
Founding partner and managing director, Active Ownership Capital S.a.r.l., Grevenmacher (Luxembourg)

— **Wolfgang Essler**, residing in Munich
(member until June 12, 2024,
Chair since June 12, 2024)
Managing director, Santo Deutschland (Holding) GmbH

— **Nicholas Haggar**,
residing in Chalfont St Giles (UK)
(member since June 12, 2024)
Chief executive officer, Healthqube Ltd.

— **Dr. Bodo Coldewey**,
residing in Edewecht
(member since June 12, 2024)
Managing director, WEGA Invest GmbH

— **Colin Michael Bond**,
residing in Zurich (Switzerland)
(member since October 1, 2024)
Retired

The following members of the Supervisory Board are members of other supervisory boards:

— **Klaus Röhrig**
Member of board of directors, Agfa-Gevaert NV ,
Member of supervisory board, Francotyp-Postalia Holding AG

— **Nicholas Haggar**
Non-executive director, Zentiva K.S. International, Prague (Czech Republic),
Independent director, Biocon Limited, Bangalore (India),
Independent director, Biocon Biologics Ltd., Bangalore (India),
Non-executive director, Biocon Biologics UK Ltd., London (UK),
Non-executive director, Biosimilars NewCo Ltd., London (UK),
Non-executive director, Biosimilar Collaborations Ireland, Ltd., Dublin (Ireland)

— **Colin Bond**
Member of board of directors, Sandoz AG, Basel (Switzerland),
Member of board of directors, BioPharma Credit Plc, London (UK)

Remuneration

During the fiscal year, the members of the Supervisory Board received total remuneration of € 211K (prior year: € 109K), while total remuneration to members of the Executive Board, within the meaning of sec. 285 no. 9 of the Commercial Code, was € 2,980K (prior year: € 1,814K), of which € 587K (prior year: € 604K) was success-based, and including € 1,096K from the granting of 22,740 subscription rights under a success-based stock option plan.

Information on shareholdings per sec. 285 no. 11 of the Commercial Code

	Share of capital (in %)	Equity (in € K)	Annual net income/loss (in € K)
FORMYCON PROJECT 201 GmbH Planegg/Martinsried, Germany	100.00	-196	0
FORMYCON PROJECT 203 GmbH Planegg/Martinsried, Germany	100.00	-2,645	88
FYB202 Project GmbH Planegg/Martinsried, Germany	100.00	35,358	21,280
Clinical Research GmbH (previously Bioeq GmbH) Holzkirchen, Germany	100.00	4,495	-78
Bioeq AG Zug, Switzerland	50.00	39,894*	24,068*

* according to IFRS

Information on auditor fees per sec. 285 no. 17 of the Commercial Code

	Fiscal year 2024	Fiscal year 2023
Audit services	631	547
Other confirmation services	969	13
Total	**1,600**	**560**

Significant events subsequent to balance sheet closing date

There have been no events of material significance which occurred following the end of the fiscal year and are not reflected in these Financial Statements.

Appropriation of profit or loss

The Executive Board proposes to carry forward the annual net loss to the next fiscal year.

Subsequent report

After the reporting date Formycon shares were included in the TecDAX. FYB203 Eylea®-Biosimilar received approval in the European Union as well as in United Kingdom and commercialization partnerships for FYB203 were agreed with Teva Pharmaceuticals International GmbH covering large parts of Europe as well as with Lotus Pharmaceutical for the Asia-Pacific region. FYB202/Otulfi® received approval in Canada and in United Kingdom.

Declaration of Conformity

The Declaration of Conformity of the German Corporate Governance Code is permanently available on our website under *https://www.formycon.com/en/investor-relations/governance/*.

Martinsried/Planegg, Germany, March 26, 2025

Dr. Stefan Glombitza

Nicola Mikulcik

Dr. Andreas Seidl

Enno Spillner

Attachment 1

Schedule of Fixed Assets for the fiscal year from Jan. 1 to Dec. 31, 2024 2024 in € K

	Changes in historical cost of acquisition					Changes in accumulated depreciation & amortization				Changes in net book value		
	Historical cost of acquisition or production at Dec. 31, 2023	Additions	Rebookings	Historical cost of disposals	Historical cost of acquisition or production at Dec. 31, 2024	Accumulated depreciation & amortization at Dec. 31, 2023	Current-year depreciation & amortization	Depreciation & write-downs on disposals	Accumulated depreciation & amortization at Dec. 31, 2024	Net book value at Dec. 31, 2023	Net book value of disposals	Net book value at Dec. 31, 2024
Intangible assets	**3,368**	**-138**	**-2**	**44**	**3,185**	**2,498**	**265**	**44**	**2,719**	**871**	**0**	**466**
Concessions, commercial property rights, and similar rights and assets, as well as licenses for such rights and assets	1,792	-138	-2	44	1,609	922	265	44	11,438	871	0	466
Goodwill	1,576	0	0	0	1,576	1,576	0	0	1,576	0	0	0
Advance payments	0	0	0	0	0	0	0	0	0	0	0	0
Property, plant and equipment	**9,737**	**1,773**	**2**	**44**	**11,468**	**5,576**	**1,115**	**32**	**6,660**	**4,161**	**0**	**4,808**
Land and buildings, including property-like rights and buildings on third-party land	651	405	32	0	1,089	578	98	0	676	73	0	412
Technical equipment and machinery	6,699	500	98	15	7,282	3,711	570	12	4,270	2,988	0	3,012
Other plant, production equipment and office equipment	2,273	746	104	29	3,095	1,287	445	20	1,711	987	0	1,383
Advanced payments and construction in progress	113	122	-233	0	2	0	2	0	2	113	0	0
Financial assets	**896,981**	**2,419**	**0**	**27,300**	**872,100**	**177,015**	**126,307**	**0**	**303,322**	**719,966**	**27,300**	**568,778**
Shares in affiliated companies	543,905	0	0	0	543,905	80,373	115,044	0	195,417	463,533	0	348,439
Loans to affiliated companies	2,000	0	0	0	2,000	0	0	0	0	2,000	0	2,000
Loans to companies in which an investment participation is held	91,300	2,419	0	27,300	66,419	0	0	0	0	91,300	27,300	66,419
Investment participations in corporations	259,776	0	0	8	259,776	96,643	11,263	0	107,906	163,133	0	151,920
Total	**910,087**	**4,054**	**0**	**27,388**	**886,753**	**185,089**	**127,688**	**75**	**312,701**	**724,998**	**27,300**	**574,052**

Attachment 2

Schedule of Receivables for the fiscal year from Jan. 1 to Dec. 31, 2024 in € K

	Dec. 31, 2024	of which due in more than 1 year	of which due within 1 year
Trade accounts receivable	3,576	0 (prior year: 0)	3,576 (prior year: 22)
Receivables from affiliated companies	16,046	0 (prior year: 0)	16,046 (prior year: 17,357)
Other assets	3,693	0 (prior year: 0)	3,693 (prior year: 4,190)
Total	**23,314**	0 (prior year: 0)	**23,314 (prior year: 21,569)**

Attachment 3

Schedule of Liabilities for the fiscal year from Jan. 1 to Dec. 31, 2024 in € K

	Dec. 31, 2023	of which due within 1 year	of which due in 1-5 years	of which due in more than 5 years	of which pledged as security	Type and form of security
Trade accounts payable	5,270	5,270 (prior year: 7,827)	0 (prior year: 0)	0 (prior year: 0)	0	
Liabilities toward affiliated companies	12,000	12,000 (prior year: 9,000)	0 (prior year: 0)	0 (prior year: 0)	0	
Other liabilities	1,595	941 (prior year: 21,383)	655 (prior year: 716)	0 (prior year: 0)	655	'Industry-customary conditional retention of title
Total	**18,865**	**18,211**	**655**	**0**	**655**	

Responsibility statement

To the best of our knowledge, we confirm that these Financial Statements of Formycon AG, prepared in accordance with the applicable accounting principles under German law, provide a true and fair view of the assets, liabilities, financial position and profit or loss of the Company, and that the Combined Management Report includes a fair review of the development and performance of the business and the position of the Company and the Group, along with a description of the principal risks and opportunities associated with its expected future development.

Martinsried/Planegg, Germany, March 26, 2025

Dr. Stefan Glombitza

Nicola Mikulcik

Dr. Andreas Seidl

Enno Spillner

Independent auditor's report

To Formycon AG, Planegg-Martinsried

Report on the audit of the annual financial statements and the combined management report

Audit Opinions

We have audited the annual financial statements of Formycon AG, Planegg-Martinsried, which comprise the balance sheet as at December 31, 2024, and the income statement for the financial year from January 1 to December 31, 2024, and notes to the financial statements, including the recognition and measurement policies presented therein. In addition, we have audited the combined management report of Formycon AG and the Group (the "combined management report") for the financial year from January 1 to December 31, 2024.

In accordance with the German legal requirements, we have not audited the content of those parts of the combined management report listed in the "Other Information" section of our auditor's report.

The combined management report contains cross-references marked as unaudited that are not required by law. In accordance with German legal requirements, we have not audited the content of these cross-references or the information to which the cross-references relate.

In our opinion, based on the findings of our audit, the accompanying annual financial statements

— the accompanying annual financial statements comply, in all material respects, with the requirements of German commercial law applicable to business corporations and give a true and fair view of the assets, liabilities and financial position of the Company as at December 31, 2024 and of its financial performance for the financial year from January 1 to December 31, 2024 in compliance with German Legally Required Accounting Principles, and

— the accompanying combined management report as a whole provides an appropriate view of the Company's position. In all material respects, this combined management report is consistent with the annual financial statements, complies with German legal requirements and appropriately presents the opportunities and risks of future development. Our audit opinion on the combined management report does not cover the content of those parts of the combined management report listed in the "Other information" section. The combined management report contains cross-references marked as unaudited that are not required by law. Our audit opinion does not cover these cross-references or the information to which the cross-references relate.

Pursuant to § 322 Abs. 3 Satz 1 HGB, we declare that our audit has not led to any reservations relating to the legal compliance of the annual financial statements and of the combined management report.

Basis for the audit opinions

We conducted our audit of the annual financial statements and of the combined management report in accordance with § 317 HGB and the EU Audit Regulation (No 537/2014, referred to subsequently as "EU Audit Regulation") and in compliance with German Generally Accepted Standards for Financial Statement Audits promulgated by the Institut der Wirtschaftsprüfer [Institute of Public Auditors in Germany] (IDW). Our responsibilities under those requirements and principles are further described in the "Auditor's Responsibilities for the Audit of the Annual Financial Statements and of the Combined

Management Report" section of our auditor's report. We are independent of the Company in accordance with the requirements of European law and German commercial and professional law, and we have fulfilled our other German professional responsibilities in accordance with these requirements. In addition, in accordance with Article 10 (2) (f) of the EU Audit Regulation, we declare that we have not provided non-audit services prohibited under Article 5 (1) of the EU Audit Regulation. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinions on the annual financial statements and on the combined management report.

Key audit matters in the audit of the annual financial statements

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the annual financial statements for the financial year from January 1 to December 31, 2024. These matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

> *The recoverability of the material shares in affiliated companies, loans to affiliated companies and investments as well as the carrying amount of the contingent purchase price payment resulting from the corporate transaction to acquire the shares in Bioeq AG (FYB201) and FYB202 Project GmbH*

Please refer to Note 3 for information on the accounting policies applied. Explanations on business development can be found in the combined management report in the section on net assets, sales and earnings development.

The risk for the financial statements

In the annual financial statements of Formycon AG as of December 31, 2024, shares in affiliated companies in the amount of EUR 348.4 million, loans to affiliated companies in the amount of EUR 68.4 million and investments in the amount of EUR 151.9 million are reported under financial assets. In addition, EUR 305.4 million of this amount is attributable to contingent purchase price payments, which are also reported as other provisions. Financial assets account for 87% of the balance sheet total and therefore have a significant impact on the company's financial position. The main shares in affiliated companies, loans to affiliated companies and investments are attributable to Bioeq AG (FYB201) and FYB202 Project GmbH.

Financial assets are recognized at cost. To this end, the company capitalizes the contingent purchase price payments as contingent acquisition costs and increase in the acquisition price of the financial assets. If impairment is expected to be permanent, the financial assets are recognized at the lower fair value. The company determines the fair value of shares in affiliated companies and investments using the discounted cash flow method. For loans, the present value of expected future payments is also used analogously, depending on the remaining term.

The cash flows used for the discounted cash flow method are based on investment-specific plans for the next 17 or 16 years, which are extrapolated using assumptions for market sales of the products FYB 201 (Bioeq AG) and FYB202 via long-term amortization rates. The respective capitalization interest rate is derived from the return on a risk-adequate alternative investment or, for the portion of the contingent purchase price payment, from the average market interest rate from the past seven financial years corresponding to the remaining term. If the fair value is lower than the carrying amount, qualitative and quantitative criteria are used to determine whether the impairment is expected to be permanent.

The calculation of fair value using the discounted cash flow method is complex and highly dependent on the company's estimates and judgments with regard to the assumptions made. This applies in particular to the estimation of future market sales and long-term depreciation rates, the determination of the capitalization interest rate from the return on a risk-adequate alternative investment and the

assessment of the permanence of the impairment. Since the end of the 2024 financial year, the business prospects in the biosimilar area have deteriorated sustainably due to intense competition. This is leading to increasing price discounts and lower market sales. Against this backdrop, the company recognized impairment losses on financial assets in the amount of EUR 126.3 million in the 2024 financial year.

There is a risk for the financial statements that impairments have not been sufficiently determined and that the material shares and loans to affiliated companies as well as the investments are therefore not recoverable. There is also a risk for the financial statements that the fair values for the contingent purchase price payments have not been determined in an appropriate amount.

Our audit approach

We obtained an understanding of the Company's process for the valuation of shares/participations and the determination of the fair values for the contingent purchase price payments by obtaining explanations from employees in the finance department. Based on the information obtained during our audit, we also assessed the shares and loans to affiliated companies and investments for which there were indications of impairment.

We then assessed the appropriateness of the key assumptions and the company's valuation method with the involvement of our valuation specialists. For this purpose, we discussed the expected cash flows and the assumed long-term amortization rates with those responsible for planning. We also reconciled the projections with other internally available forecasts, e.g. for tax purposes, and the budget prepared by the executive directors. In addition, we assessed the consistency of the assumptions with external market estimates.

We compared the assumptions and data underlying the discount rate, in particular the risk-free interest rate, the market risk premium and the beta factor, with our own assumptions and publicly available data.

Furthermore, we satisfied ourselves of the company's forecasting accuracy to date by comparing forecasts from previous financial years with the results actually realized and analyzing deviations.

To assess the methodologically and mathematically appropriate implementation of the valuation method, we verified the valuation performed by the company using our own calculations and analyzed deviations.

In order to take into account the existing forecast uncertainty, we also examined the effects of possible changes in the discount rate and the expected cash inflows on the fair value by calculating alternative scenarios and comparing them with the valuation results of the company (sensitivity analysis).

Our conclusions

The procedure underlying the impairment test of shares and loans to affiliated companies and investments is appropriate and in line with the valuation principles. The determination of the fair values from contingent purchase price payments is consistent with the valuation principles. The assumptions and data used by the company are appropriate.

Other information

The Management Board or the Supervisory Board is responsible for the other information. The other information comprises the following components of the combined management report, the content of which has not been audited

— the combined corporate governance statement of the company and the Group included in chapter "Corporate governance statement pursuant to § 289f and § 315d HGB" of the combined management report, and

— the information contained in the combined management report that is not part of the management report and is marked as unaudited.

Our opinions on the annual financial statements and on the combined management report do not cover the other information, and consequently we do not express an opinion or any other form of assurance conclusion thereon.

In connection with our audit, our responsibility is to read the other information referred to above and, in doing so, consider whether the other information

— - is materially inconsistent with the annual financial statements, with the audited disclosures in the combined management report or our knowledge obtained in the audit, or

— - otherwise appears to be materially misstated.

Responsibilities of the Executive Board and the Supervisory Board for the annual financial statements and the combined management report

The Management Board is responsible for the preparation of the annual financial statements that comply, in all material respects, with the requirements of German commercial law applicable to business corporations, and that the annual financial statements give a true and fair view of the assets, liabilities, financial position and financial performance of the Company in compliance with German Legally Required Accounting Principles. In addition, the Management Board is responsible for such internal control as they, in accordance with German Legally Required Accounting Principles, have determined necessary to enable the preparation of annual financial statements that are free from material misstatement, whether due to fraud (i.e. accounting fraud or fraudulent misrepresentation) or error.

In preparing the annual financial statements, the Management Board is responsible for assessing the company's ability to continue as a going concern. Furthermore, it is responsible for disclosing, as applicable, matters related to going concern. In addition, it is responsible for financial reporting based on the going concern basis of accounting unless factual or legal circumstances indicate otherwise. Furthermore, the Executive Board is responsible for the preparation of the combined management report that, as a whole, provides an appropriate view of the Company's position and is, in all material respects, consistent with the annual financial statements, complies with German legal requirements and appropriately presents the opportunities and risks of future development. In addition, the Executive Board is responsible for such arrangements and measures (systems) as it has considered necessary to enable the preparation of a combined management report that is in accordance with the applicable German legal requirements, and to be able to provide sufficient appropriate evidence for the assertions in the combined management report.

The Supervisory Board is responsible for overseeing the company's financial reporting process for the preparation of the annual financial statements and of the combined management report.

Auditor's responsibilities for the audit of the annual financial statements and of the combined management report

Our objectives are to obtain reasonable assurance about whether the annual financial statements as a whole are free from material misstatement, whether due to fraud or error, and whether the combined management report as a whole provides an appropriate view of the Company's position and, in all material respects, is consistent with the annual financial statements and the knowledge obtained in the audit, comply with German legal requirements and appropriately present the opportunities and risks of future development, as well as to issue an auditor's report that includes our audit opinions on the annual financial statements and on the combined management report.

Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with § 317 HGB and the EU Audit Regulation and in compliance with German Generally Accepted Standards for Financial Statement Audits promulgated by the Institut der Wirtschaftsprüfer [Institute of Public Auditors in Germany] (IDW) will always detect a material misstatement. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate,

they could reasonably be expected to influence the economic decisions of users taken on the basis of these annual financial statements and combined management report.

We exercise professional judgment and maintain professional skepticism throughout the audit. In addition

— Identify and assess the risks of material misstatement of the annual financial statements and of the combined management report, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our audit opinions. The risk of not detecting a material misstatement resulting from fraud is higher than the risk of not detecting a material misstatement resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

— Obtain an understanding of internal control relevant to the audit of the annual financial statements and of arrangements and measures (systems) relevant to the audit of the combined management report in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control or on the effectiveness of these arrangements and measures.

— Evaluate the appropriateness of accounting policies used by the Executive Board and the reasonableness of accounting estimates and related disclosures made by the Executive Board.

— Conclude on the appropriateness of the Board of Management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in the auditor's report to the related disclosures in the annual financial statements and in the combined management report or, if such disclosures are inadequate, to modify our respective audit opinions. We draw our conclusions on the basis of the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to be able to continue as a going concern.

— Evaluate the overall presentation, structure and content of the annual financial statements, including the disclosures, and whether the annual financial statements present the underlying transactions and events in a manner that the annual financial statements give a true and fair view of the assets, liabilities, financial position and financial performance of the Company in compliance with German Legally Required Accounting Principles.

— Evaluate the consistency of the combined management report with the annual financial statements, its conformity with German law, and the view of the Company's position it provides.

— Perform audit procedures on the prospective information presented by the Executive Board in the combined management report. On the basis of sufficient appropriate audit evidence we evaluate, in particular, the significant assumptions used by the Executive Board as a basis for the prospective information, and evaluate the proper derivation of the prospective information from these assumptions. We do not express a separate audit opinion on the forward-looking statements or on the underlying assumptions. There is a significant unavoidable risk that future events will differ materially from the forward-looking statements.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with the relevant independence requirements, and communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, the actions taken or safeguards applied to address independence threats.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the annual financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter.

Other legal and regulatory requirements

Statement on the non-issuance of an audit opinion on the electronic reproduction of the annual financial statements and the combined management report to be prepared for publication purposes in accordance with Section 317 (3a) HGB

We were engaged to perform an assurance engagement in accordance with Section 317 (3a) HGB to obtain reasonable assurance about whether the reproduction of the annual financial statements and the combined management report (hereinafter also referred to as "ESEF documents") prepared for publication purposes complies in all material respects with the requirements of Section 328 (1) HGB for the electronic reporting format ("ESEF format").

We do not express an audit opinion on the ESEF documents. Due to the significance of the matter described below, we have not been able to obtain sufficient appropriate audit evidence as a basis for our opinion on the ESEF documents.

As the Executive Board has not provided us with any ESEF documents for audit up to the date of our auditor's report, we do not express an opinion on the ESEF documents.

The executive directors of the company are responsible for the preparation of the ESEF documents including the electronic reproduction of the annual financial statements and the combined management report in accordance with § 328 Abs. 1 Satz 4 Nr. 1 HGB.

Furthermore, the company's Management Board is responsible for such internal control as it determines is necessary to enable the preparation of ESEF documents that are free from material non-compliance, whether due to fraud or error, with the requirements of Section 328 (1) HGB for the electronic reporting format.

The Supervisory Board is responsible for overseeing the process of preparing the ESEF documents as part of the financial reporting process.

It is our responsibility to perform an assurance engagement on the ESEF documents in accordance with § 317 Abs. 3a HGB and IDW Auditing Standard: Assurance in Accordance with § 317 Abs. 3a HGB on the Electronic Reproduction of Financial Statements and Management Reports Prepared for Publication Purposes (IDW PS 410 (06.2022)) [if conducive to an understanding of the report in an international environment: and International Standard on Assurance Engagements 3000 (Revised)]. Based on the matter described above, we have not been able to obtain sufficient appropriate audit evidence to provide a basis for our opinion on the ESEF documents.

Other information according to Art. 10 EU-APrVO
We were elected as auditor by the annual general meeting on June 12, 2024. We were engaged by the audit committee on January 30, 2025. We

have been the auditor of Formycon AG without interruption since the financial year 2022, including one financial year during which the Company met the definition of a public-interest entity within the meaning of Section 316a sentence 2 HGB without interruption.

We declare that the audit opinions expressed in this auditor's report are consistent with the additional report to the audit committee pursuant to Article 11 of the EU Audit Regulation (audit report).

We have performed the following services, which are not disclosed in the annual financial statements or in the combined management report of the audited company, in addition to the audit of the financial statements for the audited company or for the companies controlled by it:

In addition to the consolidated financial statements, we have audited the annual financial statements and the combined management report of Formycon AG and reviewed interim financial statements. The other assurance services relate to the issuance of a comfort letter and the audit of pro forma financial information.

Auditor responsible for the audit

The auditor responsible for the audit is Alexander Hutzler.

Munich, 26 March 2025

KPMG AG
Wirtschaftsprüfungsgesellschaft
[Original German version signed by:]

Hutzler	Ratkovic
Wirtschaftsprüfer [German Public Auditor]	Wirtschaftsprüfer [German Public Auditor]

Imprint

Formycon AG
Fraunhoferstraße 15
82152 Planegg-Martinsried
Germany

+49 89 864 667 100
info@formycon.com
www.formycon.com

Date of publication
March 27, 2025

Photos
Martin Joppen
Hagen Brede
Adobe Stock
Formycon AG